Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types.
BACKGROUND Immune infiltration of the tumor microenvironment has been associated with improved survival for some patients with solid tumors. The precise makeup and prognostic relevance of immune infiltrates across a broad spectrum of tumors remain unclear. METHODS Using mRNA sequencing data from The Cancer Genome Atlas (TCGA) from 11 tumor types representing 3485 tumors, we evaluated lymphocyte and macrophage gene expression by tissue type and by genomic subtypes defined within and across tumor tissue of origin (Cox proportional hazards, Pearson correlation) We investigated clonal diversity of B cell infiltrates through calculating B cell receptor (BCR) repertoire sequence diversity. All statistical tests were two sided. RESULTS High expression of T cell and B cell signatures predicted improved overall survival across many tumor types including breast, lung, and melanoma (breast CD8_T_Cells hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.16 to 0.81, P .01; lung adenocarcinoma B_Cell_60gene HR 0.71, 95% CI 0.58 to 0.87, P 7.80E 04; melanoma LCK HR 0.86, 95% CI 0.79 to 0.94, P 6.75E 04) Macrophage signatures predicted worse survival in GBM, as did B cell signatures in renal tumors (Glioblastoma Multiforme [GBM] macrophages HR 1.62, 95% CI 1.17 to 2.26, P .004; renal: B_Cell_60gene HR 1.17, 95% CI 1.04 to 1.32, P .009) BCR diversity was associated with survival beyond gene segment expression in melanoma (HR 2.67, 95% CI 1.32 to 5.40, P .02) and renal cell carcinoma (HR 0.36, 95% CI 0.15 to 0.87, P .006) CONCLUSIONS These data support existing studies suggesting that in diverse tissue types, heterogeneous immune infiltrates are present and typically portend an improved prognosis. In some tumor types, BCR diversity was also associated with survival. Quantitative genomic signatures of immune cells warrant further testing as prognostic markers and potential biomarkers of response to cancer immunotherapy.
Journal of the National Cancer Institute